Equillium, Inc. announced that it has surpassed the interim enrollment target for the Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD). Equillium expects to deliver the results of the EQUATOR interim data review to Ono during the third quarter, which will then trigger Ono?s three-month option exercise period to acquire Equillium?s rights to itolizumab.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.47 USD | -2.00% | +0.68% | +103.32% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+103.32% | 52.88M | |
+42.60% | 739B | |
+32.34% | 598B | |
-5.74% | 353B | |
+17.79% | 318B | |
+3.37% | 285B | |
+16.47% | 240B | |
+9.26% | 210B | |
-5.07% | 206B | |
+6.74% | 164B |
- Stock Market
- Equities
- EQ Stock
- News Equillium, Inc.
- Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease